By Darlene Dobry:: Pharmaceutical Strategies
As the COVID-19 Pandemic continues to hit the world’s economies Healthcare Systemsand communities on their knees that Pharma Industry seems to be the shining hope of bringing us back to normal. Might the industry respond to this global one Healthcare Crisis is that Rx for his tarnished reputation?
The Pharmaceutical industry has long been at the center of a firestorm consistently referred to as one of the most unpopular and suspicious industries in the world Gallup poll. Given the media coverage of CEOs and companies’ financial claims, patent attempts, illegal activity and questionable practices, legal settlements, price discounts, product recalls, and more recently its role in the devastating opioid epidemic, this is not surprising. While the high level of suspicion and contempt of the public are directed against “greedy” pharmaceuticals, Prescription drug expenses represents between 10% and 12% of total US health care costs and now, in our most urgent time, we turn to this industry to help fight COVID-19. This pandemic brought the committed, community-minded side of Pharma at the forefront in his quick and relentless pursuit of the best science to solve this crisis.
Pharmaceuticals Collaboration for COVIDs Rx
There are brilliant and talented people in Dozens of companiesBoth established manufacturers and small start-ups work tirelessly to find a solution. Early efforts designed and produced test assays to test the Health community Identify and confirm the virus. The expanded focus is now on proven treatments and vaccines. We see unexpected partnerships and creativity exists in the race for answers that address the crippling public health effects that disrupt the economy and supply chains. Thomas Cueniwho heads the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) noted in Geneva: “The industry, which has traditionally been highly competitive, has come together.”
For example, rivals to like Sanofi and GSK are working to bring their innovative technologies together for a vaccine. Astra-Zeneca and Oxford University Sign Global Development and Distribution Agreement for CO-19 Vaccine, Takeda and CoVIg-19 Alliance Regeneron and Sanofi are investing in plasma therapies and conducting clinical trials for their jointly commercialized rheumatoid arthritis drug Kevzara. Pfizer and BioNTech are working together on an mRNA vaccine. There are an impressive number of ongoing studies evaluating existing drugs for other diseases, including Gileads Remdesivir which now has FDA emergency approval, and is Gilead Sciences applies For full US approval, specialty biotech companies like Moderna and Novavax have also entered the race and are looking for their vaccine candidates.
Pharma investments and innovations during COVID-19
Beyond drug treatment and vaccine development, the industry has also brought in new ingenuity and investment in fighting COVID-19 and supporting the health system. Johnson & Johnson pledges $ 300 million over ten years to help frontline workers Astra-Zeneca Donating 9 million face masks to protect healthcare workers around the world, companies who use theirs 3d printing PPE and equipment manufacturing skills and consumer product companies that manufacture hand sanitizer.
This industry, its brilliant researchers and dedicated staff are unwavering in their mission to be part of the solution by investing in unknowns despite the risk, diverting focus from other commercially available / development resources, and creating groundbreaking scientific innovations to combat COVID-19 . With the sheer number of companies in the race, we stand the best chance of finding solutions and the scale to keep up with alarming projections of cases. It also helps promote competition and promote fair prices. In spite of Pharmaengagement There are still critics who attribute pharma efforts to capitalizing on a crisis and focusing solely on profit. For those who feel that pharma should not profit from deep investment, it is currently difficult to set a price for overcoming this enemy.
Pharma Marcom & PR during COVID
Knowing that consumer Look at brands and companies showing social responsibility, philanthropic, and community support, other industry leaders, and I agree that pharma has an opportunity to grow out of some of the negative perceptions and recognition of its essential role in moving away from it “StayatHome” to “StayHealthy”. According to a recent publication, public opinion is gradually improving during this pandemic Harris poll. From a marketing and PR perspective, I hope Pharmaceutical Research and Manufacturers of America (PhRMA) will seize this moment to raise public awareness and highlight the corporate commitment and investment behind the scenes of this pandemic.
This is not selfish. This is about scientific innovation, leadership in times of crisis, corporate responsibility and saving lives. During this time, the industry should continue to prove its thought leaders through scientific publications and act as the voice of experts. As consumers seek information about viruses, vaccines, and treatments, pharma must ensure that the public has access to credible, science-based content across media channels. Accepted consequences Because of this pandemic, there is also a tremendous need for mental health and wellbeing. With the significant investment and access to mental health solutions and services, Pharma can answer that call as well.
Pharmaceutical marketing & Healthcare Marketing | COVID & beyond
As an advertising and communications professional, now is the time to improve and be an even truer and more innovative partner to pharmaceutical marketing agencies. As our pharmaceutical, medical and healthcare customers focus their efforts on COVID-19, our own industry needs to be even more proactive and creative. Let’s strategically bring in pharmaceuticals inventive marketing communication ideas and messaging programs to keep their brands and marketing more relevant during the COVID pandemic. Let’s help Pharmas reach their increasingly “distant” customers and patients more effectively. Let’s get better search rankings by creating more useful and authoritative content to keep the online engaged healthcare audience informed. Let’s examine corporate campaigns and grassroots programs to bring medical and pharmaceutical companies closer to their patient communities and really build reputations. As social media experts, let us help pharma be consistently compliant and proactively trustworthy participants in conversations Diseases & Conditions. Let’s elevate the core values of the pharmaceutical industry currently on display through successfully inventive creativity and sophisticated innovation. As partners, let us work tirelessly to create and focus insightful insights into the heroic endeavors of our client partners – healthcare and medical innovators working to create “life changing” differences in today’s life-changing public health crisis .
COVID and Healthcare Marketing – Related Articles:|
Note: We are not the author of this content. For the Authentic and complete version,
Check its Original Source